Biotech investors operate on a fundamentally different calculus than generalist tech VCs. They're underwriting science risk with decade-long timelines and binary outcomes, which means they care less about your TAM slide and more about your de-risking roadmap: what's the next value inflection point, how clean is your preclinical package, and what does the regulatory path actually look like? Most biotech funds have partners with PhDs or MD backgrounds who will dig into your mechanism of action, so don't oversimplify the science—but also don't bury the commercial story. The founders who struggle here are the ones who pitch like they're defending a thesis rather than building a company. Lead with the milestone that unlocks the next round, not the elegance of your biology.

​

Know that biotech VCs think in portfolio construction terms. They're balancing high-risk platform bets against more de-risked asset plays, so understanding where your company fits on that spectrum helps you target the right partners. Specialist funds like Flagship, ARCH, or Third Rock often incubate or co-create companies from scratch—they're looking for transformational science they can shape. Corporate venture arms from pharma (Pfizer Ventures, Novartis Venture Fund, etc.) care about strategic pipeline fit and may offer regulatory expertise and BD intros, but can complicate future exits if acquirers see you as "tied" to a competitor. One practical note: biotech investors expect you to have thought seriously about reimbursement and payer dynamics, not just FDA approval. A drug that gets approved but doesn't get paid for is a failed investment. If you can articulate the clinical-commercial bridge clearly, you'll stand out from most pitches they see.